Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Other Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Other Non-Current Assets for 3 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 14.51% to $5.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.7 million, a 14.51% decrease, with the full-year FY2024 number at $6.8 million, up 115.9% from a year prior.
  • Other Non-Current Assets was $5.7 million for Q3 2025 at Inhibrx Biosciences, down from $6.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.8 million in Q4 2024 to a low of $3.2 million in Q4 2023.
  • A 3-year average of $6.1 million and a median of $6.7 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 115.9% in 2024, then decreased 14.51% in 2025.
  • Inhibrx Biosciences' Other Non-Current Assets stood at $3.2 million in 2023, then surged by 115.9% to $6.8 million in 2024, then decreased by 16.0% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Other Non-Current Assets are $5.7 million (Q3 2025), $6.8 million (Q2 2025), and $6.8 million (Q1 2025).